Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates ...

Researchers have discovered new insights into tumor-induced B cell changes in blood and bone marrow of triple negative breast cancer patients. The findings show two distinct patterns of B cell ...

At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ...

Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...

Black women are more likely than white women to die from even the most treatable types of breast cancer, a study published ...

PORTSMOUTH, Va. — The American Cancer Society is making a plea to lawmakers for more funding for cancer research. Portsmouth cancer survivor Kim Anderson is helping make that plea. “I was ...

Immunotherapy, which works by enabling the body's immune system to recognize and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large ...

Peter Schmid, MD, PhD, discusses his key takeaways from the phase 3 KEYNOTE-522 trial and the updated findings presented at ...